Literature DB >> 8812865

Isolation and characterization of human tissue kallikrein produced in Escherichia coli: biochemical comparison to the enzymatically inactive prokallikrein and methionyl kallikrein.

H S Lu1, Y R Hsu, L I Lu, D Ruff, D Lyons, F K Lin.   

Abstract

This report describes bacterial expression, isolation, and characterization of human tissue kallikrein recombinantly produced in Escherichia coli. Successful production of enzymatically active recombinant human kallikrein requires the following processes: expression, solubilization and refolding of prokallikrein, thermolysin activation, and chromatographic separation. All experimental data confirmed that bacterially derived human kallikrein is properly folded and exhibits expected biochemical functions. As confirmed by SDS-PAGE and reverse-phase HPLC, recombinant kallikrein is apparently pure and is devoid of reduced or other partially folded kallikrein forms. Recombinant kallikrein behaves as a monomeric molecule in solution and exhibits full enzymatic activity in hydrolyzing peptide substrates. The molecule can bind to aprotinin to form kallikrein-inhibitor complex at a 1:1 molar ratio. Peptide mapping analysis derived from pepsin digestion of recombinant kallikrein assigned five disulfide bonds which match those of porcine kallikrein predicted from X-ray structure. Peptides containing unpaired cysteines or mispaired disulfide bonds were not detected. Both properly folded prokallikrein and methionyl kallikrein, containing a propeptide and an initiator methionine at their N-termini, respectively, were also produced and isolated. These two molecules are structurally similar to recombinant kallikrein, but are not enzymatically active.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812865     DOI: 10.1006/prep.1996.0094

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.

Authors:  B A Katz; B Liu; M Barnes; E B Springman
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

2.  Expression of active human tissue-type plasminogen activator in Escherichia coli.

Authors:  J Qiu; J R Swartz; G Georgiou
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

3.  Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Authors:  Xavier Charest-Morin; Arvind Raghavan; Matthew L Charles; Tadeusz Kolodka; Johanne Bouthillier; Mélissa Jean; Mark S Robbins; François Marceau
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

4.  In silico and in vivo analyses of the mutated human tissue plasminogen activator (mtPA) and the antithetical effects of P19 silencing suppressor on its expression in two Nicotiana species.

Authors:  Mahshid Amiri; Mokhtar Jalali-Javaran; Raheem Haddad; Parastoo Ehsani
Journal:  Sci Rep       Date:  2018-09-19       Impact factor: 4.379

5.  Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus.

Authors:  Tadeusz Kolodka; Matthew L Charles; Arvind Raghavan; Ilian A Radichev; Christina Amatya; Jacob Ellefson; Alexei Y Savinov; Abhijeet Nag; Mark S Williams; Mark S Robbins
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.